NewAmsterdam provides pipeline update; cash ~$729M; EMA decision expected 2H26

NewAmsterdam Pharma Co N.V.

Unaudited cash, cash equivalents and marketable securities ~$729M as of Dec 31, 2025.
EMA approval decision for obicetrapib monotherapy and FDC expected in 2H26.
PREVAIL CVOT overall MACE event rate tracking in line with BROADWAY; fully enrolled with >9,500 patients.
First patient enrolled in RUBENS Phase 3 trial for metabolic syndrome; topline data expected year-end 2026.
Plans to initiate first dedicated Alzheimer's trial in 2026 based on positive biomarker data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.